Upper Respiratory Tract Infection
Conditions
Brief summary
This is a Phase 1, single-dose, two-period study that will consist of a combined screening and baseline period and an open-label treatment period. Subjects will be enrolled when they experience an Upper Respiratory Tract Infection with nasal congestion and edema.
Interventions
DRUGARS-1 with URTI
ARS-1
DRUGARS-1 without URTI
ARS-1 without URTI
Sponsors
ARS Pharmaceuticals, Inc.
Study design
Allocation
NON_RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
No
Inclusion criteria
* Treatment Period 1 only, subject has symptoms of an URTI at time of dosing based on the clinical judgement and the positive infectious cause of URTI to be confirmed by Respiratory Pathogens Panel. * Has body weight more than 55 kg for male and 50 kg for female and body mass index between 18 and 32 kg/m2, inclusive. * Has no declared medical history of hypertension and cardiovascular disease in the last 10 years. * At screening, has stable vital signs in the following ranges (after 5 minutes of rest): * SBP ≥90 and ≤140 mmHg * DBP ≥50 and ≤90 mmHg * HR ≥45 and ≤100 beats per minute (bpm) * Is a nonsmoker within the previous 2 months (calculated from first dosing) and does not use tobacco-containing products.
Exclusion criteria
* Has a stated history of clinically significant gastrointestinal, renal, hepatic, neurologic, hematologic, endocrine, oncologic, pulmonary, immunologic, psychiatric, or cardiovascular disease or any other condition which, in the opinion of the Investigator, would jeopardize the safety of the subject or impact the validity of the study results. * Has current or past history of clinically significant asthma or angioedema. * Has prior nasal fractures, severe nasal injuries or history of nasal disorders that could interfere with nasal spray administration. * Has any clinically significant medical condition or physical exam (PE) finding as deemed inappropriate by the Investigator. * Has abnormal cardiovascular exam at screening including any prior history of myocardial infarction or clinically significant abnormal ECG. * Subject reports they have had significant traumatic injury, major surgery or open biopsy within 30 days prior to study screening. * Subject reports they have donated blood including platelets or plasma only or had an acute loss of blood (\>50 mL) during the 30 days before study drug administration or intends to donate blood or blood products within 30 days after the completion of the study. * Has a history (within 12 months before screening) of drug use, or has a positive test for drugs of abuse at screening or upon admittance to the study center, or has a stated history of alcohol abuse. * Has been on an abnormal diet during the four (4) weeks from Day 0. 10. Has participated in a clinical trial within 30 days prior to the first dose of study drug. 11\. Has had treatment with any adrenaline or noradrenaline containing products within 7 days of Day 0. 12\. Has inadequate or difficult venous access that may jeopardize the quality or timing of the PK samples.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| To evaluate the bioavailability (Cmax) of ARS-1 after intranasal administration | Day -1 to Day 30 | Blood samples will be collected to measure plasma concentrations of adrenaline |
| To evaluate the bioavailability (AUC0-t) of ARS-1 after intranasal administration | Day -1 to Day 30 | Blood samples will be collected to measure plasma concentrations of adrenaline |
| To evaluate the bioavailability (tmax) of ARS-1 after intranasal administration | Day -1 to Day 30 | Blood samples will be collected to measure plasma concentrations of adrenaline |
Countries
Australia
Outcome results
None listed